Literature DB >> 19564884

Gender differences in the cardiovascular effect of sex hormones.

Cristiana Vitale1, Michael E Mendelsohn, Giuseppe M C Rosano.   

Abstract

The higher incidence of cardiovascular disease in men than in women of similar age, and the menopause-associated increase in cardiovascular disease in women, has led to speculation that gender-related differences in sex hormones have a key role in the development and evolution of cardiovascular disease. Compelling data have indicated that sex differences in vascular biology are determined not only by gender-related differences in sex steroid levels, but also by gender-specific tissue and cellular differences that mediate sex-specific responses. In this Review, we describe the sex-specific effects of estrogen and testosterone on cardiovascular risk, direct vascular effects of these sex hormones, and how these effects influence development of atherosclerosis. Cardiovascular effects of exogenous hormone administration are also discussed. Importantly, evidence has indicated that estrogens alone or in combination with progestins in postmenopausal women increase cardiovascular risk if started late after menopause, but that it possibly has beneficial cardiovascular effects in younger postmenopausal women, although data on long-term testosterone therapy are lacking. Hormone therapy should not be considered solely for primary prevention or treatment of cardiovascular disease at this time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19564884     DOI: 10.1038/nrcardio.2009.105

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  141 in total

1.  The relation of endogenous sex steroid hormone concentrations to serum lipid and lipoprotein levels in postmenopausal women.

Authors:  J A Cauley; J P Gutai; L H Kuller; J G Powell
Journal:  Am J Epidemiol       Date:  1990-11       Impact factor: 4.897

2.  Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.

Authors:  Nancy J Brown; Amira Abbas; Daniel Byrne; John A Schoenhard; Douglas E Vaughan
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

3.  Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury.

Authors:  Gary Pare; Andrée Krust; Richard H Karas; Sonia Dupont; Mark Aronovitz; Pierre Chambon; Michael E Mendelsohn
Journal:  Circ Res       Date:  2002-05-31       Impact factor: 17.367

4.  Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta.

Authors:  Yan Zhu; Zhao Bian; Ping Lu; Richard H Karas; Lin Bao; Daniel Cox; Jeffrey Hodgin; Philip W Shaul; Peter Thoren; Oliver Smithies; Jan-Ake Gustafsson; Michael E Mendelsohn
Journal:  Science       Date:  2002-01-18       Impact factor: 47.728

5.  Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor.

Authors:  Joanne E Nettleship; T Hugh Jones; Kevin S Channer; Richard D Jones
Journal:  Circulation       Date:  2007-11-05       Impact factor: 29.690

6.  Estradiol and metabolic syndrome in older italian men: The InCHIANTI Study.

Authors:  Marcello Maggio; Fulvio Lauretani; Gian Paolo Ceda; Stefania Bandinelli; Shehzad Basaria; Giuseppe Paolisso; Claudio Giumelli; Michele Luci; Samer S Najjar; E Jeffrey Metter; Giorgio Valenti; Jack Guralnik; Luigi Ferrucci
Journal:  J Androl       Date:  2008-12-04

7.  Endogenous sex hormones and progression of carotid atherosclerosis in elderly men.

Authors:  Majon Muller; Annewieke W van den Beld; Michiel L Bots; Diederick E Grobbee; Steven W J Lamberts; Yvonne T van der Schouw
Journal:  Circulation       Date:  2004-04-19       Impact factor: 29.690

8.  Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes.

Authors:  Michiaki Fukui; Yoshihiro Kitagawa; Naoto Nakamura; Mayuko Kadono; Shinichi Mogami; Chizuko Hirata; Naoko Ichio; Katsuya Wada; Goji Hasegawa; Toshikazu Yoshikawa
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

9.  Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

Authors:  Peter Collins; Lori Mosca; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Messan G Amewou-Atisso; Mark B Effron; Sherie A Dowsett; Elizabeth Barrett-Connor; Nanette K Wenger
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

10.  Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness.

Authors:  M R Adams; J K Williams; J R Kaplan
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

View more
  88 in total

1.  Estrogenic Impact on Cardiac Ischemic/Reperfusion Injury.

Authors:  Sivaporn Sivasinprasasn; Krekwit Shinlapawittayatorn; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cardiovasc Transl Res       Date:  2016-01-19       Impact factor: 4.132

2.  Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.

Authors:  Zijun Meng; Hongjiang Jing; Lu Gan; Hua Li; Bingde Luo
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 3.  Gender differences in hypertension and hypertension awareness among young adults.

Authors:  Bethany Everett; Anna Zajacova
Journal:  Biodemography Soc Biol       Date:  2015

4.  Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions.

Authors:  Eline M Rodenburg; Bruno H Stricker; Loes E Visser
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 5.  Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women.

Authors:  Enrique F Schisterman; Sunni L Mumford; Lindsey A Sjaarda
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

Review 6.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

7.  Hormone phase influences sympathetic responses to high levels of lower body negative pressure in young healthy women.

Authors:  Charlotte W Usselman; Chantelle A Nielson; Torri A Luchyshyn; Tamara I Gimon; Nicole S Coverdale; Stan H M Van Uum; J Kevin Shoemaker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-10-12       Impact factor: 3.619

Review 8.  Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review.

Authors:  Horacio Medina de Chazal; Marco Giuseppe Del Buono; Lori Keyser-Marcus; Liangsuo Ma; F Gerard Moeller; Daniel Berrocal; Antonio Abbate
Journal:  J Am Coll Cardiol       Date:  2018-10-16       Impact factor: 24.094

Review 9.  Gender and anti-thrombotic therapy: from biology to clinical implications.

Authors:  Rossella Marcucci; Gabriele Cioni; Betti Giusti; Cinzia Fatini; Lorenza Rossi; Maddalena Pazzi; Rosanna Abbate
Journal:  J Cardiovasc Transl Res       Date:  2014-01-28       Impact factor: 4.132

Review 10.  Sex and gender differences in myocarditis and dilated cardiomyopathy.

Authors:  DeLisa Fairweather; Leslie T Cooper; Lori A Blauwet
Journal:  Curr Probl Cardiol       Date:  2013-01       Impact factor: 5.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.